OverviewSuggest Edit

Immune Design is a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is focused on oncology and have engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells, or CTLs, to fight cancer. Its immuno-oncology product candidates are being developed in two separate approaches: one that targets specific antigens and/or epitopes; and an alternative approach that leverages the endogenous antigens found in the tumor microenvironment via intratumoral immunization. The specific antigen approach uses selected antigens that are also present in the patient’s tumor so that the immune system will be educated to recognize the tumor antigen and kill tumor cells expressing the antigen.

TypePublic
Founded2008
HQSeattle, US
Websiteimmunedesign.com

Latest Updates

Employees (est.) (Dec 2018)48(-12%)
Revenue (FY, 2018)$2.2 M(-69%)
Share Price (Apr 2019)$5.9

Key People/Management at Immune Design

Carlos Paya

Carlos Paya

President and Chief Executive Officer
Stephen R. Brady

Stephen R. Brady

Executive Vice President, Strategy & Finance
Wayne Gombotz

Wayne Gombotz

Chief Development Officer
Frank J Hsu

Frank J Hsu

Vice President, Head of Oncology
Sandy Mohan

Sandy Mohan

Vice President, Quality & Compliance
Heidi Petersen

Heidi Petersen

Vice President of Regulatory Affairs
Show more

Immune Design Office Locations

Immune Design has offices in Seattle and South San Francisco
Seattle, US (HQ)
1616 Eastlake Ave E #310
South San Francisco, US
601 Gateway Blvd #250
Show all (2)

Immune Design Financials and Metrics

Immune Design Revenue

Immune Design's revenue was reported to be $2.20 m in FY, 2018
USD

Revenue (FY, 2018)

2.2m

Gross profit (FY, 2018)

761.0k

Gross profit margin (FY, 2018), %

34.7%

Net income (FY, 2018)

(54.8m)

EBIT (FY, 2018)

(57.0m)

Market capitalization (4-Apr-2019)

282.9m

Closing stock price (4-Apr-2019)

5.9

Cash (31-Dec-2018)

77.9m
Immune Design's current market capitalization is $282.9 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018

Revenue

9.5m13.3m7.2m2.2m

Cost of goods sold

774.0k481.0k84.0k1.4m

Gross profit

8.7m12.8m7.1m761.0k

Gross profit Margin, %

92%96%99%35%
Quarterly
USDQ2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.1m3.5m1.8m4.7m1.9m1.1m8.2m5.5m729.0k516.0k503.0k755.0k462.0k

Cost of goods sold

18.0k31.0k44.0k298.0k22.0k253.0k72.0k37.0k18.0k16.0k7.0k140.0k32.0k

Gross profit

1.0m3.5m1.7m4.4m1.8m880.0k8.1m5.4m711.0k500.0k496.0k615.0k430.0k

Gross profit Margin, %

98%99%98%94%99%78%99%99%98%97%99%81%93%
USDY, 2018

Revenue/Employee

45.8k

Financial Leverage

1.1 x
Show all financial metrics

Immune Design Operating Metrics

FY, 2016

Patents (Foreign)

19

Patents (US)

16

Phase I Trials Products

1

Phase II Trials Products

3
Show all operating metrics

Immune Design Online and Social Media Presence

Embed Graph

Immune Design News and Updates

Thinking about buying stock in Apple, Canopy Growth Corp, Immune Design, Roku Inc or Zosano Pharma?

NEW YORK, Feb. 22, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, CGC, IMDZ, ROKU, and ZSAN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Immune Design Corp.

NEW YORK, Feb. 21, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Immune Design Corp. (NASDAQ: IMDZ) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Merck Sharp & Dohme Corp. (NYSE: MRK)....

SHAREHOLDER ALERT: WeissLaw LLP Investigates Immune Design Corp.

NEW YORK, Feb. 21, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Immune Design Corp. ("IMDZ" or the "Company") (NASDAQ: IMDZ) in connection with the proposed acquisition of the Company by...

UPDATE 1-Merck to buy immunotherapy developer Immune Design for $300 mln

Merck & Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs.

Immune Design Reports Increased Overall Response Rate and Longer Progression Free Survival of Patients with Follicular Lymphoma Treated in a Randomized Trial with a Combination Regimen of G100 and Pembrolizumab

SEATTLE and SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 02, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced long-term follow up results from a randomized Phase 2 clinical trial of 10 ug intratumor…

Immune Design to Present at Jefferies 2018 London Healthcare Conference

SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2018 London …
Show more

Immune Design Blogs

Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update Content Import Wed, 08/01/2018 - 16:03 Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update Aug 01, 2018 This release is a backfill from a News Wire …

Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update

Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update Content Import Wed, 07/25/2018 - 08:03 Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update Jul 25, 2018 This release is a backfill from a News Wir…

Immune Design Frequently Asked Questions

  • When was Immune Design founded?

    Immune Design was founded in 2008.

  • Who are Immune Design key executives?

    Immune Design's key executives are Carlos Paya, Stephen R. Brady and Wayne Gombotz.

  • How many employees does Immune Design have?

    Immune Design has 48 employees.

  • What is Immune Design revenue?

    Latest Immune Design annual revenue is $2.2 m.

  • What is Immune Design revenue per employee?

    Latest Immune Design revenue per employee is $45.8 k.

  • Who are Immune Design competitors?

    Competitors of Immune Design include XBiotech, Cleveland BioLabs and Aptevo Therapeutics.

  • Where is Immune Design headquarters?

    Immune Design headquarters is located at 1616 Eastlake Ave E #310, Seattle.

  • Where are Immune Design offices?

    Immune Design has offices in Seattle and South San Francisco.

  • How many offices does Immune Design have?

    Immune Design has 2 offices.